Business Context and Reporting Period
This Form 8-K was filed by Tivic Health Systems, Inc. on May 13, 2024, regarding events occurring on May 9, 2024. The provided metadata identifies Valion Bio, Inc., but the filing itself identifies the registrant as Tivic Health Systems, Inc. The filing concerns a registered public offering and related financing agreements.
Financing and Key Financial Metrics
- The company agreed to sell 4,710,000 common shares, 4,710,000 Series A warrants, and 7,065,000 Series B warrants.
- The securities were sold in units consisting of one common share, one Series A warrant, and 1.5 Series B warrants, at $0.85 per unit.
- The warrants were immediately exercisable at $0.85 per share, subject to adjustment. Series A warrants expire one year after issuance, and Series B warrants expire five years after issuance.
- The offering closed on May 13, 2024, with approximately $4.0 million of gross proceeds.
- Net proceeds were approximately $3.5 million after placement-agent fees, expenses, and estimated offering costs, excluding any future warrant-exercise proceeds.
- Proceeds are intended for working capital and general corporate purposes.
- The placement agent received a 7.0% cash fee of $280,245, reimbursement of $100,000 of expenses, and 188,400 warrants exercisable at $0.935 per share.
- The filing does not provide revenue, profit, cash-flow, margin, debt, or liquidity metrics for a comparable reporting period.
Material Changes and Dilution Considerations
- The transaction increased outstanding common shares by 4,710,000 shares at closing, before considering any warrant exercises.
- Common warrants provide for potential issuance of up to 11,775,000 additional common shares, comprising 4,710,000 Series A warrant shares and 7,065,000 Series B warrant shares.
- The placement-agent warrants provide for up to 188,400 additional shares.
- Full exercise of all disclosed warrants would therefore result in up to 16,673,400 shares issued in connection with the transaction, including the 4,710,000 shares sold at closing; the filing does not state the company’s pre-offering shares outstanding.
Guidance, Outlook, Risks, and Unusual Items
- The company provided no revenue or earnings guidance in the filing.
- The company agreed, subject to exceptions, not to issue or announce the issuance of additional company or subsidiary securities for six months after the offering’s closing.
- The company also agreed not to enter into variable-rate transactions involving common stock or common-stock equivalents.
- Officers and directors entered into 90-day lock-up agreements covering their company securities, subject to specified exceptions.
- The Purchase Agreement includes customary closing conditions, representations and warranties, termination rights, indemnification obligations, and continuing covenants.
- Future warrant exercises could provide additional capital but may also increase share dilution. The filing does not indicate whether any warrants have been exercised.
Most Important Facts to Verify
- Confirm the registrant’s identity: the filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Verify the final net cash received after all offering expenses and the company’s intended allocation of approximately $3.5 million.
- Verify the company’s post-offering shares outstanding and the potential dilution from the 11,775,000 common-warrant shares and 188,400 placement-agent-warrant shares.
- Review the warrant adjustment provisions, expiration dates, and exercise conditions in Exhibits 4.1 through 4.3.
- Review subsequent filings for warrant exercises, additional financings, use of proceeds, and liquidity developments.